GDF15 and ACE2 stratify COVID19 patients according to severity while ACE2 mutations increase infection susceptibility.

Margalida Torrens‐Mas; Catalina M. Perelló-Reus; Neus Trias-Ferrer; Lesly Ibargüen-González; Catalina Crespı́; Aina Maria Galmes-Panades; Cayetano Navas-Enamorado; Andrés Sánchez-Polo; Javier Pierola Lopetegui; Lluís Masmiquel; Lorenzo Socías Crespí; Carles Barceló; Marta González‐Freire

doi:10.3389/fcimb.2022.942951

Molecular BiologyFrontiers in Cellular and Infection MicrobiologyJul 22, 2022

Peer-reviewed journal article

GDF15 and ACE2 stratify COVID19 patients according to severity while ACE2 mutations increase infection susceptibility.

Margalida Torrens‐Mas iD, Catalina M. Perelló-Reus, Neus Trias-Ferrer, Lesly Ibargüen-González iD, Catalina Crespı́iD, Aina Maria Galmes-Panades iD, Cayetano Navas-Enamorado iD, Andrés Sánchez-Polo iD, Javier Pierola Lopetegui, Lluís Masmiquel iD, Lorenzo Socías Crespí, Carles Barceló iD, Marta González‐Freire iD

PDF DOI Preprint

Post to X

Threads on X Post to Bluesky Threads on Bluesky

Abstract

Coronavirus disease 19 (COVID-19) is a persistent global pandemic with a very heterogeneous disease presentation ranging from a mild disease to dismal prognosis. Early detection of sensitivity and severity of COVID-19 is essential for the development of new treatments. In the present study, we measured the levels of circulating growth differentiation factor 15 (GDF15) and angiotensin-converting enzyme 2 (ACE2) in plasma of severity-stratified COVID-19 patients and healthy control patients and characterized the in vitro effects and cohort frequency of ACE2 SNPs. Our results show that while circulating GDF15 and ACE2 stratify COVID-19 patients according to disease severity, ACE2 missense SNPs constitute a risk factor linked to infection susceptibility.